Apellis says journal published 24-month result from Phase 3 OAKS, DERBY studies

Apellis Pharmaceuticals announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating SYFOVRE for geographic atrophy secondary to age-related macular degeneration. SYFOVRE is the only treatment approved for use beyond 12 months in GA, a chronic disease and leading cause of vision loss. In the publication, both every-other-month and monthly SYFOVRE showed a clinically meaningful reduction of GA lesion growth with increasing effects over time and a well-demonstrated safety profile in a broad population of more than 1,200 patients. “These 24-month data demonstrate that SYFOVRE is a clinically meaningful treatment for GA, and we are proud these results were published in one of the world’s most prestigious peer-reviewed journals,” said Caroline Baumal, M.D., chief medical officer, Apellis. “With SYFOVRE’s approval in the United States and five additional applications under review globally, we are working urgently to bring this important treatment to patients in need worldwide.”